Strumento inattivo

Azioni Avanir Pharmaceuticals Inc

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

Avanir Pharmaceuticals : Announces Appointment of Rohan Palekar as President and Chief Executive Officer	20/01/16
Avanir Pharmaceuticals : Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer’s Disease	10/12/15
Avanir Pharmaceuticals : Announces JAMA Publication of Phase II Study Results Showing AVP-923 Significantly Reduced Agitation in Patients with Alzheimer's Disease	22/09/15
Avanir Pharmaceuticals : Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026	11/08/15
Avanir Pharmaceuticals : Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II Study at Alzheimer's Association International Conference	23/07/15

Dirigenti	Titolo	Età	Da
Dan Dalton CMP	Compliance Officer	-	01/06/16
Kelly Parker IRO	Public Communications Contact	-	01/06/15
Aneta Ferguson LAW	General Counsel	-	01/01/15

Amministratori	Titolo	Età	Da
Donald Hayden CHM	Chairman	68	-
Robert McQuade BRD	Director/Board Member	67	-
Thomas DesRosier BRD	Director/Board Member	69	-

Settore

	Variaz. 1 gen.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31%	103 Mrd
REGENERON PHARMACEUTICALS, INC.	+0,56%	95,28 Mrd
ARGENX SE	+1,69%	22,15 Mrd
BIONTECH SE	-17,37%	21,02 Mrd
GENMAB A/S	-9,30%	18,15 Mrd
WUXI APPTEC CO., LTD.	-41,01%	16,74 Mrd
BEIGENE, LTD.	-14,85%	16,05 Mrd
NEUROCRINE BIOSCIENCES, INC.	+3,21%	13,68 Mrd
SAREPTA THERAPEUTICS, INC.	+33,54%	12,17 Mrd